Kymera Therapeutics Inc. debuted on NASDAQ Friday by pricing its upsized IPO of 8.68 million common shares at $20 each as it eyes gross proceeds of $173.3 million. By the end of the day, Kymera stock (NASDAQ:KYMR) had soared 66.3%, with shares closing at $33.26 each. Read More
A third child with X-linked myotubular myopathy (XLMTM) has died after receiving the higher of two doses of an experimental gene therapy for the rare disease under development at Audentes Therapeutics Inc. Preliminary findings indicate that the immediate cause of death was gastrointestinal bleeding, Audentes said. The trial, testing AT-132 (resamirigene bilparvovec), was already on an FDA clinical hold. Read More
San Diego-based Anaptysbio Inc.’s phase II blowup with anti-IL-33 monoclonal antibody etokimab in chronic rhinosinusitis with nasal polyps (CRwNP), disclosed Aug. 10, followed the compound’s mid-stage atopic dermatitis (AD) fizzle in November of last year, and raised questions not only about the lead candidate but also about the target. Read More
HONG KONG Researchers from the Massachusetts Institute of Technology’s (MIT) research enterprise in Singapore, known as Singapore-MIT Alliance for Research and Technology (SMART), have found a way to not just reverse antibiotic resistance but also increase sensitivity in some bacteria, using hydrogen sulfide. Read More
HONG KONG –Celltrion Group is partnering with Intract Pharma Ltd. to jointly develop an oral tablet form of infliximab. “Celltrion will supply the drug material through clinical evaluation and into the market, while Intract will be responsible for performing clinical studies,” Bill Lindsay, the CEO of Intract, told BioWorld. Read More
BioWorld looks at translational medicine, including: Mechanisms of retinopathy come into focus; New partner in crime for AHR; Multiple sclerosis’ early days; MMA induces EMT; CAR T cells for inhibition; Islet organoids can evade immune attack, Cross-reactive immunity helps antitumor response; How antidepressants inhibit fibrosis; Just add fever. Read More
The number of FDA approvals tracked by BioWorld have continued their steady incline, with a total of 129 logged through July, placing 2020 at a five-year high. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Auris, Genmab, Lung, Medicenna, Novartis, Silence, Sorrento, Technovax. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alkermes, Astrazeneca, Biomarin, Genmab, Kazia, Miragen, Opthea, Vertex. Read More
